Literature DB >> 24801230

Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease.

Ming-Chih Lin1.   

Abstract

BACKGROUND: The comparative effectiveness of intravenous immunoglobulin (IVIG) for Kawasaki disease was regarded as inconclusive in the international guidelines. However, several new evidences have been published in recent years. DATA SOURCES: A literature search of PubMed was conducted using key words of "Kawasaki disease or mucocutaneous lymph node syndrome" and "immunoglobulin" in combination. Only original articles published after 2004 were selected. A total of 813 papers were found in PubMed. These papers were screened manually by their titles and abstracts.
RESULTS: Patients treated with IVIG prepared by betapropiolactonation might have worse outcome (a higher non-responsive rate in one report and a higher rate of coronary aneurysm in two reports). Storage of IVIG in acidic solution might be correlated with a higher rate of coronary aneurysm (two reports).
CONCLUSIONS: Different processes of preparation and conditions of preservation of IVIG may have profound effects on its clinical effectiveness. Randomized controlled studies are needed to further elucidate this issue.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24801230     DOI: 10.1007/s12519-014-0479-8

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  43 in total

1.  Oligoclonal IgA response in the vascular wall in acute Kawasaki disease.

Authors:  A H Rowley; S T Shulman; B T Spike; C A Mask; S C Baker
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

2.  Lessons from Kawasaki disease: all brands of IVIG are not equal.

Authors:  E Richard Stiehm
Journal:  J Pediatr       Date:  2006-01       Impact factor: 4.406

3.  Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.

Authors:  S Khan; P C Doré; W A C Sewell
Journal:  Pediatr Allergy Immunol       Date:  2008-03       Impact factor: 6.377

4.  Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999-2002.

Authors:  Hiroshi Yanagawa; Yosikazu Nakamura; Mayumi Yashiro; Ritei Uehara; Izumi Oki; Kazunori Kayaba
Journal:  Pediatr Int       Date:  2006-08       Impact factor: 1.524

5.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

6.  Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study.

Authors:  A Suzuki; S Miyagawa-Tomita; K Komatsu; T Nishikawa; Y Sakomura; T Horie; M Nakazawa
Journal:  Circulation       Date:  2000-06-27       Impact factor: 29.690

7.  Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.

Authors:  Cedric Manlhiot; Pascal N Tyrrell; Lisa Liang; Adelle R Atkinson; Wendy Lau; Brian M Feldman
Journal:  Pediatrics       Date:  2008-02-25       Impact factor: 7.124

8.  Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004.

Authors:  Zhong-Dong Du; Di Zhao; Junbao Du; Yong-Lan Zhang; Yao Lin; Chong Liu; Tuohong Zhang
Journal:  Pediatr Infect Dis J       Date:  2007-05       Impact factor: 2.129

9.  Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits.

Authors:  M Iwata; T Shimozato; H Tokiwa; E Tsubura
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  Syndrome of inappropriate anti-diuretic hormone in Kawasaki disease.

Authors:  Jiro Mori; Masaru Miura; Hiroyuki Shiro; Kenichiro Fujioka; Takeo Kohri; Tomonobu Hasegawa
Journal:  Pediatr Int       Date:  2011-06       Impact factor: 1.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.